InterMune Pharmaceuticals, Inc. (Bu...
InterMune Pharmaceuticals, Inc. (Burlingame, CA) announced positive interim deductions of a Phase 4 clinical trial comparing the use of Infergen (interferon alfacon-1) plus ribavirin and the use of Rebetron (inteferon alfa-2b plus ribavirin) for the treatment of chronic hepatitis C infections. A total of 127 enthralls were randomized to receive
|